ASH 2020 - Multiple Myeloma

Preliminary results from the phase 1b/2 CARTITUDE-1 study reveal early, deep, and durable responses and a safety profile consistent with prior studies with a single low-dose infusion of ciltacabtagene autoleucel in heavily pretreated patients with RRMM. Read More ›

Updated analysis of the phase 1 CRB-401 study supports a favorable clinical benefit–risk profile for the BCMA-directed CAR T-cell therapy, idecabtagene vicleucel, in RRMM at target dose levels of ≥150 × 106 CAR+ T-cells. Read More ›